- dynamic transmission
- approaches and applications
- decision analysis
- risk analysis
- benefit-cost analysis
- cost-effectiveness analysis
- technology assessment
- operations research
- chronic disease/risk
- global governance
- economics/finance
- health/medicine
- latin america & caribbean
- europe
- asia & pacific
- oceania
Resources Repository
-
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Cost-Effectiveness Analysis | Dynamic Transmission | Health/Medicine | Economics/Finance | Asia & Pacific | Latin America & Caribbean | Global Governance | Mathematical Models | Infectious Diseases | Child/Nutrition | Health Systems | Climate/Environment -
ArticlePublication 2016Funding Gap for Immunization Across 94 Low- and Middle-Income Countries
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 …
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 low- and middle-income countries over the five-year period of 2016–2020. Vaccine financing by country governments, GAVI, and other development sources was forecasted for vaccine, supply chain, and service delivery based on an analysis of comprehensive multi-year plans together with a series of scenarios. The authors found that that delivery of full vaccination programs across the 94 countries would result in a total…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Asia & Pacific | Latin America & Caribbean | Global Governance | Costing Methods | Mathematical Models | Infectious Diseases | Health Systems | Sub-Saharan Africa | Middle East & North Africa -
ArticlePublication 2016Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to …
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to the health service provider. Effective approaches to increase the implementation of guidance are needed. Since investment in activities that improve implementation competes for funding against other health generating interventions, it should be assessed in term of its costs and benefits. In 2010, the National Institute for Health and Care Excellence released a clinical guideline recommending natriuretic peptide (NP) testing in…
Operations Research | Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Europe | Chronic Disease/Risk | Health Outcomes | Health Systems | Clinical Care -
ArticlePublication 2016An Economic Evaluation of the PEN Program in Indonesia
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) …
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) introduced the Package of Essential Noncommunicable disease (PEN) interventions. Several countries, including Indonesia, implemented the PEN program. To assess the value of the investment in the current program, an economic evaluation of the program was conducted with collaboration between the Ministry of Health in Indonesia, the WHO, and the International Decision Support Initiative (iDSI). This study evaluated the delivery of…
Technology Assessment | Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Asia & Pacific | Chronic Disease/Risk | Priority Setting/Ethics | Health Systems | Government/Law -
ArticlePublication 2013Estimated Mortality Impact of Vaccinations 2011–2020 in 73 GAVI Alliance Countries
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted …
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese…
Dynamic Transmission | Health/Medicine | Economics/Finance | Asia & Pacific | Latin America & Caribbean | Global Governance | Health Outcomes | Mathematical Models | State-Transition | Microsimulation | Infectious Diseases | Science/Technology | Sub-Saharan Africa | Middle East & North Africa -
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Cost-Effectiveness Analysis | Health/Medicine | Oceania | Asia & Pacific | Chronic Disease/Risk | Priority Setting/Ethics | Infectious Diseases | Mental Health | Health Systems -
ArticlePublication 2019Long-Term Cost-Effectiveness of Obesity Prevention Interventions in the Early Years of Life
This analysis estimated the long-term health benefits and health care cost-savings of reductions in body …
This analysis estimated the long-term health benefits and health care cost-savings of reductions in body mass index (BMI) for the Australian population of children aged between 2 and 5 years. A proportional multistate, multiple cohort, lifetable model estimated the health benefits and health care cost-savings related to hypothetical reductions in BMI, informed by a scoping review of systematic reviews reporting the effectiveness of obesity prevention interventions in preschool aged children. Results suggested significant potential for…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Oceania | Chronic Disease/Risk | Child/Nutrition | Health Systems | Clinical Care -
ArticlePublication 2016Mexico's SSB Tax Policy Impact on Diabetes and Cardiovascular Disease: Modeling Study
In 2014, Mexico instituted a nationwide tax on sugar-sweetened beverages (SSBs) in order to reduce …
In 2014, Mexico instituted a nationwide tax on sugar-sweetened beverages (SSBs) in order to reduce the high level of SSB consumption, a preventable cause of diabetes and cardiovascular disease (CVD). In this analyses, a computer simulation model of CVD was used to project potential long-range health and economic impacts of SSB taxation in Mexico. Two main scenarios were modeled: (1) a 10% reduction in SSB consumption (corresponding to the reduction observed after tax implementation) and…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Latin America & Caribbean | Chronic Disease/Risk | Mathematical Models | Microsimulation | Policy/Regulation | Food/Agriculture | Government/Law -
ArticlePublication 2016Health and Economic Benefits of Public Financing of Epilepsy Treatment in India
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of …
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of publicly financed national epilepsy programs in India that provide (1) first line antiepilepsy drugs (AEDs), (2) first- and second-line AEDs, and (3) first- and second-line AEDs and surgery. Outcome measures include disability-adjusted life years (DALYs) averted, and cost per DALY averted. Economic benefit measures estimated include out-of-pocket (OOP) expenditure averted and money-metric value of insurance. All three scenarios represent a…
Cost-Effectiveness Analysis | Health/Medicine | Economics/Finance | Asia & Pacific | Chronic Disease/Risk | Priority Setting/Ethics | Microsimulation